Exploring the Growth Trajectory of Amgen’s Repatha
Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries. Amgen’s Repatha is a human monoclonal antibody that inhibits proprotein convertase kexin type nine (or PCSK9). The drug has been approved in more than 50 regions, including the United States, Japan, Canada, and the European Union.